Cathie Wood

Person

Last mentioned: 3h ago

Stories mentioning Cathie Wood 2

pharma Neutral

ARK Invest Doubles Down on Tempus AI Amid Precision Medicine Volatility

Cathie Wood's ARK Investment Management has purchased $2 million worth of Tempus AI shares, reinforcing its position in the precision medicine firm despite a 15% year-to-date decline. The move underscores Wood's commitment to 'coiled spring' AI and biotech assets, even as her flagship funds face significant performance headwinds compared to the broader market.

3 sources
funding Neutral

Cathie Wood’s ARK Invest Doubles Down on CRISPR Therapeutics Amid Market Dip

ARK Invest, led by Cathie Wood, has significantly increased its position in CRISPR Therapeutics (CRSP), signaling continued high conviction in the gene-editing pioneer despite recent market fluctuations. This move highlights Wood's strategy of doubling down on disruptive genomic technologies during periods of valuation compression.

2 sources